Moderna vaccine for South African Covid variant starts trial

Moderna is experimenting with several potential methods of combating new variates of the virus, with a view to potentially offering new or booster shots.

Trials of the new vaccine are due to start in the US.

It comes after studies suggested that current vaccines offer less protection against the South African variant, which has a key mutation – E484K – that is thought to help the virus evade parts of the immune system.

The mutation has been worrying scientists and is also found in the Brazil variant of the virus as well as some cases of the variant originally identified in Kent.

Moderna is looking at whether an additional booster shot targeting the South African variant could be given to people, and is working on a combined jab that mixes its current vaccine with the new one.

The UK has ordered 17 million doses of Moderna’s original vaccine, with delivery expected from the spring.

READ MORE:

• 'Sewer of misinformation' around coronavirus vaccines, minister warns
• The tales this Risca boy invented about his cats have been turned into a book
• Covidiots fined after police break up house party

On Wednesday, Professor Sarah Gilbert, from the University of Oxford, said current Covid-19 vaccines are unlikely to see a “cliff edge” fall in their effectiveness when faced with new variants.

She told MPs on the Commons Science and Technology Committee there are good signs that coronavirus variants will not suddenly start escaping from the effectiveness of vaccines.

Oxford and AstraZeneca are running clinical trials from the early summer with batches of their new vaccine aimed at tackling variants.

A decision will then be taken over the summer on whether booster jabs should be offered in the autumn to tackle variants.